Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Wall Street's M&A Chatter From September 18: Walgreens-Rite Aid, Northrup Grumman-Orbital ATK, Itron-Silver Spring Networks

Benzinga.com  September 19, 2017

Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”

GlobeNewswire September 19, 2017

Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx

GlobeNewswire September 18, 2017

Ultragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash

GlobeNewswire September 18, 2017

The Market In 5 Minutes

Benzinga.com  September 14, 2017

Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosumab Data in X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) at ASBMR

GlobeNewswire September 11, 2017

Ultragenyx to Present at the Morgan Stanley Global Healthcare Conference

GlobeNewswire September 6, 2017

Ultragenyx to Present at the Baird 2017 Global Healthcare Conference

GlobeNewswire August 31, 2017

Ultragenyx and Kyowa Hakko Kirin Announce Submission of Burosumab’s Biologics License Application in the US

GlobeNewswire August 24, 2017

Ultragenyx Announces Burosumab Data Presentations at ASBMR 2017 Annual Meeting

GlobeNewswire August 24, 2017

15 Biggest Mid-Day Losers For Wednesday

Benzinga.com  August 23, 2017

Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy

GlobeNewswire August 22, 2017

Ultragenyx Reports Second Quarter 2017 Financial Results and Corporate Update

GlobeNewswire July 27, 2017

Ultragenyx to Host Conference Call for Second Quarter 2017 Financial Results and Corporate Update

GlobeNewswire July 21, 2017

Ultragenyx Provides Regulatory Update on Burosumab (KRN23)

GlobeNewswire June 23, 2017

Ultragenyx to Present at Goldman Sachs 38th Annual Global Healthcare Conference

GlobeNewswire June 7, 2017

Ultragenyx to Present at Jefferies Global Healthcare Conference

GlobeNewswire June 1, 2017

Research Reports Initiation on Biotech Stocks -- Kite Pharma, Arrowhead Pharma, Ultragenyx Pharma, and Jazz Pharma

PR Newswire May 31, 2017

Ultragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status

GlobeNewswire May 23, 2017

Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc.

Business Wire May 15, 2017